290 related articles for article (PubMed ID: 34206474)
1. CRISPR-Cas, a Revolution in the Treatment and Study of ESKAPE Infections: Pre-Clinical Studies.
González de Aledo M; González-Bardanca M; Blasco L; Pacios O; Bleriot I; Fernández-García L; Fernández-Quejo M; López M; Bou G; Tomás M
Antibiotics (Basel); 2021 Jun; 10(7):. PubMed ID: 34206474
[TBL] [Abstract][Full Text] [Related]
2. CRISPR in Modulating Antibiotic Resistance of ESKAPE Pathogens.
Saha U; Gondi R; Patil A; Saroj SD
Mol Biotechnol; 2023 Jan; 65(1):1-16. PubMed ID: 35939207
[TBL] [Abstract][Full Text] [Related]
3. Application of CRISPR-Cas system in the diagnosis and therapy of ESKAPE infections.
Qian Y; Zhou D; Li M; Zhao Y; Liu H; Yang L; Ying Z; Huang G
Front Cell Infect Microbiol; 2023; 13():1223696. PubMed ID: 37662004
[TBL] [Abstract][Full Text] [Related]
4. The CRISPR/Cas system as an antimicrobial resistance strategy in aquatic ecosystems.
Gupta SS; Hamza Kh M; Sones CL; Zhang X; Sivaraman GK
Funct Integr Genomics; 2024 May; 24(3):110. PubMed ID: 38806846
[TBL] [Abstract][Full Text] [Related]
5. Emerging Strategies to Combat β-Lactamase Producing ESKAPE Pathogens.
Vrancianu CO; Gheorghe I; Dobre EG; Barbu IC; Cristian RE; Popa M; Lee SH; Limban C; Vlad IM; Chifiriuc MC
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33198306
[TBL] [Abstract][Full Text] [Related]
6. Comparison of CRISPR-Cas Immune Systems in Healthcare-Related Pathogens.
Mortensen K; Lam TJ; Ye Y
Front Microbiol; 2021; 12():758782. PubMed ID: 34759910
[TBL] [Abstract][Full Text] [Related]
7. Harnessing the CRISPR-Cas Systems to Combat Antimicrobial Resistance.
Duan C; Cao H; Zhang LH; Xu Z
Front Microbiol; 2021; 12():716064. PubMed ID: 34489905
[TBL] [Abstract][Full Text] [Related]
8. Foodborne ESKAPE Biofilms and Antimicrobial Resistance: lessons Learned from Clinical Isolates.
Patil A; Banerji R; Kanojiya P; Saroj SD
Pathog Glob Health; 2021 Sep; 115(6):339-356. PubMed ID: 33851566
[TBL] [Abstract][Full Text] [Related]
9. Whole Genome Sequencing of Extended Spectrum β-lactamase (ESBL)-producing Klebsiella pneumoniae Isolated from Hospitalized Patients in KwaZulu-Natal, South Africa.
Founou RC; Founou LL; Allam M; Ismail A; Essack SY
Sci Rep; 2019 Apr; 9(1):6266. PubMed ID: 31000772
[TBL] [Abstract][Full Text] [Related]
10. Survey of clustered regularly interspaced short palindromic repeats and their associated Cas proteins (CRISPR/Cas) systems in multiple sequenced strains of Klebsiella pneumoniae.
Ostria-Hernández ML; Sánchez-Vallejo CJ; Ibarra JA; Castro-Escarpulli G
BMC Res Notes; 2015 Aug; 8():332. PubMed ID: 26238567
[TBL] [Abstract][Full Text] [Related]
11. An overview of resistance profiles ESKAPE pathogens from 2010-2015 in a tertiary respiratory center in Romania.
Peneş NO; Muntean AA; Moisoiu A; Muntean MM; Chirca A; Bogdan MA; Popa MI
Rom J Morphol Embryol; 2017; 58(3):909-922. PubMed ID: 29250670
[TBL] [Abstract][Full Text] [Related]
12. Phenotypic and genotypic detection methods for antimicrobial resistance in ESKAPE pathogens (Review).
Muntean MM; Muntean AA; Preda M; Manolescu LSC; Dragomirescu C; Popa MI; Popa GL
Exp Ther Med; 2022 Aug; 24(2):508. PubMed ID: 35837033
[TBL] [Abstract][Full Text] [Related]
13. Mechanisms of Antimicrobial Resistance in ESKAPE Pathogens.
Santajit S; Indrawattana N
Biomed Res Int; 2016; 2016():2475067. PubMed ID: 27274985
[TBL] [Abstract][Full Text] [Related]
14. Alternatives for the treatment of infections caused by ESKAPE pathogens.
da Rosa TF; Coelho SS; Foletto VS; Bottega A; Serafin MB; Machado CS; Franco LN; de Paula BR; Hörner R
J Clin Pharm Ther; 2020 Aug; 45(4):863-873. PubMed ID: 32339305
[TBL] [Abstract][Full Text] [Related]
15. Bacteriophages for ESKAPE: role in pathogenicity and measures of control.
Patil A; Banerji R; Kanojiya P; Koratkar S; Saroj S
Expert Rev Anti Infect Ther; 2021 Jul; 19(7):845-865. PubMed ID: 33261536
[TBL] [Abstract][Full Text] [Related]
16. Antibacterial activity of medicinal plants against ESKAPE: An update.
Bhatia P; Sharma A; George AJ; Anvitha D; Kumar P; Dwivedi VP; Chandra NS
Heliyon; 2021 Feb; 7(2):e06310. PubMed ID: 33718642
[TBL] [Abstract][Full Text] [Related]
17. Emerging Strategies to Combat ESKAPE Pathogens in the Era of Antimicrobial Resistance: A Review.
Mulani MS; Kamble EE; Kumkar SN; Tawre MS; Pardesi KR
Front Microbiol; 2019; 10():539. PubMed ID: 30988669
[TBL] [Abstract][Full Text] [Related]
18. Cracking the Challenge of Antimicrobial Drug Resistance with CRISPR/Cas9, Nanotechnology and Other Strategies in ESKAPE Pathogens.
Zohra T; Numan M; Ikram A; Salman M; Khan T; Din M; Salman M; Farooq A; Amir A; Ali M
Microorganisms; 2021 Apr; 9(5):. PubMed ID: 33946643
[TBL] [Abstract][Full Text] [Related]
19. Strategies to Overcome Antimicrobial Resistance in Nosocomial Infections, A Review and Update.
Bakhtiyari N; Farajnia S; Ghasemali S; Farajnia S; Pourmohammad A; Saeidvafa S
Infect Disord Drug Targets; 2024 Jan; ():. PubMed ID: 38284691
[TBL] [Abstract][Full Text] [Related]
20. Genome plasticity as a paradigm of antibiotic resistance spread in ESKAPE pathogens.
Das S; Bombaywala S; Srivastava S; Kapley A; Dhodapkar R; Dafale NA
Environ Sci Pollut Res Int; 2022 Jun; 29(27):40507-40519. PubMed ID: 35349073
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
